Biotech Upcoming data

Quarter 4 2018

Ticker	Phase	Drug	Notes
ACRS	2	ATI-502	data end of year
ALDX	3	Reproxalap	Allergic conjunctivitis data end of quarter or 1Q '19
ALKS	3	ALKS 3831-ENLIGHTEN-2	Top-line results (fall)
AVEO	3	TIVO-3	due to slower enrollment, data is now in Q4
BHVN	2	Trigriluzole	Top-line data
BLPH	3	INOvation-1	pulmonary arterial hypertension (PAH), with top-line data for the complete study anticipated around the end of the year
CMRX	2	CMX001	IV Brincidofovir for treatment of Viral infections
CMTA	3	MOVE trial	evaluating palovarotene. Fibrodysplasia
FOMX	3	FX 2016-11 and FX2016-12	topical minocycline foam 1.5%, for the treatment of rosace. Top-line early fourth quarter.
GILD	2	GS-9674	Clinical data end of year. Liver diseases
GLPG	3	FINCH 2	Topline data 2H 2018
GTHX	2a	trilaciclib	triple-negative breast cancer. trilaciclib for patients undergoing chemotherapy, are expected in the fourth quarter of 2018.
GTXI	2	ASTRID	Top-line result expected early Q4
KPTI	2b	SADAL	for the treatment of patients with relapsed or refractory DLBCL
KURA	2	Tipifarnib	data from multiples phase 2 tipifarnib in solid tumor and hematologic
MNLO	2	Seropitant	Data in Refractory Chronic Cough Expected in Oct 2018.
MRNS	2	Intravenous (IV) ganaxolone	Report top-line P2 Magnolia study in women with PPD
MRNS	2	MAGNOLIA	Report top-line oral ganaxolone data from Amaryllis study in women with moderate PPD fourth quarter 2018
NOVN	2	SB206	Viral infections data
OBSV	3	IMPLANT 2	Clinical trial of nolasiban in IVF. Also P2a PRLONG Safety, tolerability and pharmacokinetics in pregnant women, and interim efficacy .
OPHT	2a	Zimura	In April 2018, complete patients enrollments. Evaluate data at six months.
PBYI	2	CONTROL	Top-line data
PRTO	3	PATENCY-2	data Q1 '19 and possibly late '18
PULM	2a	PUR1800	for COPD
SBBP	3	COR-003-LOGICS	Topline data
SRRA	I/II	SRA737	Interim data
SYBX	1b/2a	SYNB1020	In development for the treatment hyperammonemia. Data end of 18
SYRS	2	SY-1425	Expect to Report Initial Data from Combination Arms
TCON	3	TRC105	interim analysis from the Phase 3 pivotal TAPPAS trial of TRC105 in angiosarcoma is expected in the second half of 2018.
UTHR	3	FREEDOM-EV	clinical data
VKTX	2	VK2809	data from P2 fatty liver and hypercholesterolemia data 2H 2018
VNDA	2	Tradipitant	for gastroparesis (gastroenterology) data end of year.
VTVT	3	STEADYFAST- Part B	data late 2018
XNCR	2	XmAb®5871	Systemic Lupus Erythematosus (SLE).

Quarter 3 2018

Ticker	Phase	Drug	Notes	Data Results
ALDX	2 and 3	Reproxalap Ocular	Phase 3 Allergic Conjunctivitis , P2b Dry Eye Disease, P3 Noninfectious Anterior Uveitis and P3 sjogren-Larsson Syndrome. All expected second half 2018
ALNY	3	ENVISION	interim analysis mid-2018. Givosiran (Acute Hepatic Porphyrias)
AMRN	3	REDUCE-IT	Topline results expected to be available before the end of Q3 2018
ANAB	2a	ANB020	in Eosinophilic Asthma Expected in the Third Quarter of 2018
ARGS	2	AGS-004	interim data due 2h 2018
ARNA	2	Olorinab	study in pain associated with Crohn's disease
ATNX	3	Oraxol KX-ORAX-001	second inerim analysis in 3Q 2018
ATXI	3	IV tramadol	for management of moderate to moderately severe postoperative pain in patients following bunionectomy surgery.
AXON	2	Nelotanserin	REM Behavior Disorder in subjects with LBD
AXSM	2	AXS-05	ASCEND study for major depressive disorder (MDD). Top-line results 2H '18
BLPH	3	PAH INOvation-1	The company continues to expect the readout of interim analyst in mid-2018.	DMC recommends stopping Phase 3.
BYSI	3	Piabulin	Interim P3 mid-2018
CANF	2	Namodenoson	Namodenoson in the treatment of heaptacellular carcinoma (HCC) expected later in 2018
CTIC	3	PIX306	trial of PIXUVRI, top-line results are expected 2Q	PIXUVRI did not meet endpoint
EIGR	2	Exendin 9-39 IN PBH	Exedin 9-39 phase 2 PREVENT study, and Ubenimex in Lymphedema; phase 2 ULTRA study completion.
ENTX	2	PTH (1-34) and NatPar	Complete the first part of Phase 2 in Aug 1, data in coming months. Hypoparathyroidism
ESPR	3	Bempedoic Acid	Global pivotal P3 study 2 52 weeks LDL-C
FLKS	2b	COMMEND trial FLXS-787	Topline 3q 2018	Discontinue trial
GALT	2	KEYTRUDA	enroll cohort 3 (GR-MD-02 8 mg/kg) of the pembrolizumab (KEYTRUDA) combination immunotherapy clinical trial, data mid-2018
IONS	2	AKCEA-APO(a)-LRx and AKCEA-ANGPTL3-LRx	six Phase 2 programs throughout 2018
OBSV	2B	OBE2109	due mid 2018
OCUL	3	OTX-TP	Expects topline efficacy data 2h 2018
OMER	2	OMS721	Immunoglobulin A (IgA) nephropathy.
ONCE	I/II	Hemophila A- SPK-8011	investigational gene therapy
ONCS	2b	PISCES/KEYNOTE-695	Dosing of first patient on Dec 14, 2017. data in 2018. (No specific quarter given)
OVID	2	OV101- STARS	Enrollment i n STARS trial to adolescent Angelman syndrome. Trial to be available 2H 2018	Positive data, but investors concerned stock -36.55% for the day.
PBYI	3	PB272 (neratinib)	third-line metastatic breast cancer patients in the second half of 2018
RARE	2	Crysvita (burosumab)	his is an open label Phase 2 study evaluating the safety and efficacy of burosumab in 17 adult patients with TIO.
RDHL	3	RHB-104	Topline data	Primary endpoint successfully achieved.
SCYX	2b	SCY-078	Topline data by July	positive results oral SCY-078
SPPI	2	Poziotinib	Breast Cancer. Data possibly release in fall
TGTX	3	UNITY-CLC	Top-line ORR and relapsed/refractory Chronic Lymphocytic Leukemia (CLL).
TNXP	3	HONOR study of Tonmya	Interim Analysis 3Q 2018;Topline results expected in 3Q 2018	discontinue Phase 3 HONOR
TOCA	3	TOCA 5	conducting 50% interim analysis 2H '18
TORC	2b	TORC1	top-line 16 weeks data expected 3Q. trial is designed to evaluate the safety, tolerability and efficacy of RTB101, an orally-administered selective TORC1 inhibitor,	announces 'positive' P2b RTB101
URGN	3	OLYMPUS	topline data
ZGNX	3	ZX008	Second pivotal trial Phase 3 Dravet syndrome program, STUDY 1504. Data late June-early July.	Primary endpoint achieved

Quarter 2 2018

Ticker	Phase	Drug	Notes	Data Results
ACRS	2	AT-50002 Topical	Top-line data 1H 2018	positive interim data
ALXN	3	PREVENT and ALXN210	Data mid-2018. Eculizumab- Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD)	Success
AQXP	3	AQX-1125	LEADERSHIP data	Failed to meet primary endpoint
AXSM	3	STRIDE-1	trial of AXS-05 IN TRD, top-line data 1H 2018
BMRN	2	Hemophilia A	update on the ongoing Phase 2 program with valoctocogene roxaparvovec at the World Federation of Hemophilia 2018 World Congress. May 20-24	Data were updated at World Congress
CARA	3	CR845	Acute Post-Operative Pain, data expected in 2Q	Report 'positive' topline data
CLDX	2b	METRIC	Topline data likely Q2 2018	Data failed
CLSD	2	TYBEE	Patients follow-up six months data	-32.19% Stock reaction to 'positive' data.
EDGE	3	EG-1962	Interim-topline data	data failed
ESPR	3	ASCVD and/or HeFH Statin add on	Global pivotal P3 study 1, 52 weeks long term safety.	Company press 'positive' data, but safety concerns dropped stock -35.11%.
FOMX	3	FMX103	Topline data mid 2018
GBT	3	HOPE study	Top -line clinical data by end of quarter	Primary endpoint achieved
GEMP	2B	INDIGO-1	Top-line data	Meet primary endpoint
GLMD	2b	ARREST	Phase IIB data late Q1 or early Q2 2018.	Data update stock up +151.29%
GNMX	2	AEVI-001	Phase 2 (ASCEND) for patients with ADHD. Data expected mid-2018
HRTX	2	HTX-011	data likely late Q2 for kneee arthroplasty	positive topline results. Stock up +30.13%
IDRA	2	IMO-8400	Topline data in June	miss primary endpoint
INCY	3	ECHO-301	Initial results of the ECHO-301 trial of epacadostat in melanoma and REACH 1 trial of ruxolittinib in acute GVHD	Data failed
IONS	P1/2a	IONIS-SOD1 ALS	Topline Data Mid Q2
JNCE	1/2	ICONIC	Preliminary Efficacy data in the first half of 2018	Underwhelming abstract, stock -35.20% reaction
KPTI	2	STORM	April data	Positive Phase 2a
MDGL	2	MGL-3196	Final 36-week data, top line results by end of May	MDGL-3196 Achieves Endpoints
MNLO	2	ATOMIK	atopic dermatitis data expected April 2018	Data failed
NBRV	3	LEAP 2	Data are expecting in Spring 2018	Company press lefamulin meets all primary endpoints. Stock down -16.57%
PRTA	IIb	NEOD1	Top-line data	Data failed, stock down -68.78%
SBBP	3	RECORLEV	Top-line results on track with SONICS	Positive results.
SELB	2	SEL-212	Symtomatic Gout Patients. Updated Clinical data at PANLAR Congress on Tuesday, April 10, 2018
VICL	2	HSV-2	Therapeutic Vaccine	trial vaccine did not meet primary endpoint
VTVT	3	STEADFAST	STEADFAST study (azeliragon in Alzheimer's disease) Part A early 2018	Data failed
XLRN	3	MEDALIST and BELIEVE	Data mid 2018	Achieved primary and secondary endpoints

Quarter 1 2018

Ticker	Phase	Drug	Notes	Data Results
ACOR	3	Tozadenant	Phase 3 data
AIMT	3	PALISADE	"Anticipate sharing topline in first quarter 2018"
ANAB	2	ANB020	Phase 2 data readout in adult severe peanut allergy.
ANTH	3	Sollpura-RESULT	data due end of Q1
ARGX	2	ARGX-113	Myasthenia gravis data
AXON	2	Intepirdine and Nelotanserin	January data: HEADWAY in patients with dementia with Levy bodies (DLB). subjects with Alzheimer's disease, DLB and Parkinson's disease dementia (PDD). Nelotanserin (LBD).
AXSM	3	CREATE-1	trial of AXS-02 in CRPS, interim efficacy analysis
BHVN	3	RIMEGEPANT	Top-line results
BLPH	3	INO pulse for PAH indication	Topline line data
BOLD	1/2	AT132	Phase 1/2 data readout of AT132 XLMTM
CDTX	2	STRIVE	CD101 IV
Cidara Therapeutics Inc (CDTX)	2	STRIVE	completing enrollment of the 90-patietn. P2 Rezafungin
CLSD	3	PEACHTREE	Macular Edema Associated with Non-infectious Uveitis, top line data.
CPRX	2	CMS-001	Expect top-line results from CMS-001 in first half 2018
DERM	3	CLAREOS 1 and CLAREOS 2	October 5, 2017 completes patient enrollment in Two Phase 3 pivotal trials of Olumacostat Glasaretil for the treament of Acne Vulgaris. Topline.
EARS	3	KEYZILEN	P3 TACTT3 topline data
EIGR	2	LIBERTY	Ubenimex in PAH
EYEG	3	EGP-437	Topline data
FGEN	2	FG-3019	Pancreatic caner study results
FLKS	2	FLX-787 Multiples Sclerosis	Readout data end of Q1
GEMP	2b	INDIGO-1	top-line data
GTHX	2a	trilaciclib	trilaciclib first-in-line small cell lung cancer. Data in March
IDRA	2	IMO-2125	Clinical trial of 8mg intratumoral IMO-2125 in combination with ipilimumab in anti-PD1 reffractory melanoma. ORR data
MNOV	2	mn-166	Completion enrollment news on Sept 19,2017. Final data Q1
MRNS	2	CDKL5	on-going in the Magnolia Study, with data expected in early 2018
OVID	2	STARS	Sometimes 2018
PTGX	2b	PTG-300	interim analysis early 2018
REGN	3	Praluent ODYSSEY OUTCOMES	Cardiovascular events.
TCON	2	TRAXAR trial of TRC105	Top-line data from the randomized P2
TRPX	IIa	THX-110	Tourette syndrome. Top-line anticipated in first half 2018
TTPH	3	IGNITE3	Additional data
VBLT	3	VB-111	top-line results
VICL	3	ASP0013	The multinational phase 3 registration trial in HCT recipients completed enrollment in Sept 2016 with a total 515 subjects.
VRTX	2	VX-445 and VX-659 triple combinations in CF patietns	data 1H18
VTGN	2	AV-101	P2 monotherapy study completion expected early 2018
VTVT	3	STEADFAST	STEADFAST study (azeliragon in Alzheimer's disease) Part A early 2018	Data failed

Quarter 4 2017

Ticker	Phase	Drug	Notes
ADRO	2	CRS-207 in combination with pembrolizumab	Report early observations from the ongoing phase 2 mesothelioma study
AGLE	1	AEB1102	Potential data end of year.
ANAB	2a	ANB020	Multiple Top-Line Clinical data readouts expected in second half of 2017
ARDX	3	T3MPO-2	Results of Tenapanor for IIBS-C on track early Q4
AVXL	2a	ANAVEX 2-73	PK/PD data
CALA	2	CB-839	In July 2017, Calithera initiated a phase 2 trial of CB-839 with pcitaxel in triple negative breast cancer patietns.
CLDX	2	Glembatumumab Vedotin	The company anticipated in fall of 2017
CNCE	2b	CTP-543	End of year data
CPRX	3	Firdapse®	Top-line Results expected in early December. Completes enrollment in second phase 3 trial on Oct 31,2017
CYTK	3	VITALITY-ALS	Trial of Tirasemtiv
DBVT	3	PEPITES	to report topline results from PEPITES in October 2017
EARS	3	AM-111 HEALOS	The trial enrolled 256 patients with severe to profound idiopathic sudden sensorineural hearing loss.
EIGR	2	LIMT HDV	interim data study at AASLD
GALT	2b	NASH-CX	Clinical data in December
IRWD	2	IW-1973	data from two phase IIa studies with IW-1973 in diabetic patients with hypertension are expected by end of 2017.
KDMN	2	KD025	Randomized, open-label clinical trial in idiopathic pulmonary fibrosis
KDMN	2	KD025	Randomized, open-label clinical trial in idiopathic pulmonary fibrosis and full data to severe psoriasis
KURA	2	tipifarnib	Phase 2 trial of tipifarnib in HRAS mutant SCCHN second half 2017
MDGL	2	MGL-3196 for NASH	Top-line results for the primary endpoint of the trial, the reduction of liver fat, assessed by MRI-PDFF at 12 weeks, are expected by year-end
MLNT	2/3	Taksta	exploratory trial data in refractory bone and joint infections.
MNOV	2b	SPRINT-MS/NN 102	phase 2b Trial of Ibudilast in progressive MS has been accepted for oral platform presentation at 7th Join ECTRIMS*ACTRIMS meeting October 25-28, 2017 in Paris, France
ONTX	3	INSPIRE	interim analysis anticipate in Q4
RARX	2	RA101495	Cohort B of Ra Pharma's Phase 2. The company remains on track to report additional data around year-end.
RVNC	2	RT002	RT002 injectable in management of plantar fascitis
RVNC	3	SAKURA 1&2	rt002 Injectable for the treatment of glabellar (frown) lines
SAGE	2	SAGE-217	SAGE-217 in PPD and essential tumor 2H2017
SGEN	3	ADCETRIS	Full data from ADCETRIS phase 3 ECHELON-1 trial
STML	2	SL-401	In Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Top line results in 2h17
SYRS	2	SY-1425	on track to present initial phase 2 clinical data
TGTX	2	TG-1101	multiples sclerosis trial update
VKTX	2	VK5211	Phase 2 hip fractured study full enrolled, data expected Q4 '17. From Aug 19 press released

Quarter 3 2017

Ticker	Phase	Drug	Notes
ABBV	3	SELECT-BEYOND	top-line data likely 3Q
ABUS	2	HBV	ARB1467 data
ABUS	2	ARB-1467	top-line results from the three-month bi-weekly dosing expect to be announced in September
ALDX	2A	ADX-102	Clinical trial in Dry Eye Disease
ALNY	2	hempohillia	Fitusiran PII OLE dadta
ALNY	3	APOLLO	results for Patisiran in near term
ANAB	2a	ANB020	Multiple Top-Line Clinical data Readouts expected in Second half of 2017
ANTH	2	BRIGHT	BRIGHT study of blisibimod in IgA
ARRY	3	BEACON CRC	data from the safety due at ESMO
AXON	3	Alzheimer's disease	Data to be out in September 2017
AZRX	IIa	MS1819	expect completion Phase IIa in 3Q
BLPH	2a	PH-IPF	"results of this study in near futture" -Mr. Tenenbaum
FOLD	3	SD-101	SD-101 for Epidermolysis Bullosa (EB), Top-line P3 late 3Q
GILD	2	GS-0976	NASH data
GTXI	2	Enobosarm	top-line results in 3Q
INSM	3	ARIKAYCE	data out in September
KDMN	2	KD025	Open-label, dose finding clinical trial in chronic graft-versus-host disease. Also Tesevatinib data
MDCO	3	Meropenem-Vaborbactam	TANGO 2 end of 3Q
MRNS	2	CDKL5	Phase 2 trial evaluating children with CDKL5 disorder
MRTX	2	NSCLL	AMETHYST trial
NBRV	3	Infections	LEAP 1 data.
OTIC	3	AVERTS-1	Phase 3 AVERTS-1 trial for OTIVDEX(tm) in September
RDHL	2	BEKINDA	IBS-D data in September
SAGE	3	Brexanolone in SRSE	top-line results from STATUS trial
STML	2	SL-401	top-line results in 2h17
VNDA	2	Tradipitant	study for treatment of chronic pruritus in patients with atopic dermatitis.
VSAR	3	Pediatric GHD	Top line from pediatric phase 3 Velocity trial around end of September
VSTM	3	Duvelisib	Phase 3 DUO top-line latter part of summer
ZYNE	2	FAB-C	top-line results from the FAB-C Fragile X study in September

Quarter 4 20018

Ticker	Phase	Drug	Notes	Data Results
FGEN	3	Roxadustat	topline data for anemia in chronic kidney disease

BIOTECHNOLOGY FORMULA

Total : %

08.18.18 03:13:16AM

Biotech Data Calculator

Stock Symbol:

Select Phase:

Select Disease Area:

Please select phase first

Select Category:

Disclaimer! This is NOT an investment advice. The data result herein is purely speculation only. You must do your own due diligence and mitigate your risk. You acknowledge that TradersFish.com will not be held responsible and accountable for any losses you may incur using our Biotech Data Calculator. Please consult your own financial adviser before executing trades.